Vistagen Therapeutics reported encouraging preliminary Phase 3 data for its lead candidate, fasedienol, in social anxiety disorder, marking a significant clinical milestone. The company's distinct intranasal pherine platform leverages neurocircuitry activation with ongoing trials across multiple CNS and related indications. Strategic licensing agreements with AffaMed Therapeutics for Asia and Fuji Pharma for Japan position Vistagen for regional commercialization while manufacturing remains outsourced to CDMOs. Despite substantial net losses and ongoing financing needs, the latest filings signal progress towards regulatory submissions and potential market entry.